What happened
SK Bioscience filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$117M (+9.1% year on year), an operating loss of US$30.8M and a net loss of US$25M.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$117M |
|---|---|
| Revenue vs a year earlier | +9.1% |
| Operating profit | −US$30.8M |
| Net income | −US$25M |
| Period | Q1 2026 (consolidated) |
| Filed | 2026-05-06, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260506800645 → open original filing |
Source: DART. Information only, not investment advice.